BioSpace News Archive

Deals

Deal Spree Continues as Celgene Nabs Juno in $9B Deal

The announcement sent shares of Juno soaring more than 27 percent in pre-market trading to $86.26.

January 22, 2018
·
2 min read
·
Alex Keown
Business

Sanofi to Eliminate 400 U.S. Jobs

Sanofi has announced major restructuring, which will involve layoffs.

January 22, 2018
·
2 min read
·
Mark Terry
Ascletis Plans $100M C Round; Then Hong Kong IPO

The company will use the money to fund clinical trials and develop a marketing operation.

January 22, 2018
·
1 min read
Why Booming Celltrion Started Crashing Last Week

Celltrion, the little-known South Korean biotech company that surged into the ranks of the world’s most-traded stocks at the start of 2018, may finally be coming down to Earth.

January 22, 2018
·
1 min read
Pharm Country

Rho to Showcase its Regulatory Expertise During Innovative Regulatory Pathways Summit

Rho will highlight its regulatory expertise to accelerate the drug review and approval process at the Innovative Regulatory Pathways Summit, taking place on January 29-30 in Arlington, Virginia.

January 22, 2018
·
1 min read
FDA

Medrobotics Wins FDA Nod for World’s First and Only Flexible Transabdominal and Transthoracic Robotic Scope

This clearance reaffirms the Company’s progress to develop transformative products for single-port general, gynecological, thoracic and urological surgeries.

January 22, 2018
·
2 min read
Biotech Beach

IASIS Technologies Release: Clinical Study Shows Good News for Concussion Sufferers

There is good news for those who suffer from concussions.

January 22, 2018
·
2 min read
Novo Nordisk A/S: Share Repurchase Programme – Jan. 22, 2018

Under the programme initiated 1 November 2017, Novo Nordisk will repurchase B shares for an amount up to DKK 4.8 billion in the period from 1 November 2017 to 30 January 2018.

January 22, 2018
·
1 min read
Business

TissUse Reports Progress Made in Collaboration With AstraZeneca

TissUse continues their successfulcollaboration with Astra to establish relevant MPS models based on TissUse’s Multi-Organ-Chip technology.

January 22, 2018
·
2 min read
Drug Development

NANOBIOTIX Presents First Promising Data From Phase I/II Liver Cancers Trial of NBTXR3 at the American Society of Clinical Oncology Gastrointestinal Annual Meeting

The product has demonstrated a very good safety profile, with no adverse event (serious or not) related to NBTXR3 occurred and no dose-limiting toxicity (DLT).

January 22, 2018
·
9 min read